Literature DB >> 27452484

Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study.

Andrzej Pająk, Krystyna Szafraniec, Maciej Polak, Maria Polakowska, Magdalena Kozela, Walerian Piotrowski, Magdalena Kwaśniewska, Ewa Podolecka, Krystyna Kozakiewicz, Andrzej Tykarski, Tomasz Zdrojewski, Wojciech Drygas.   

Abstract

INTRODUCTION Lowering exposure to dyslipidemias is one of the biggest challenges in cardiovascular disease prevention.  OBJECTIVES The aim of the study was to describe the prevalence of dyslipidemias and treatment of hypercholesterolemia in Poland, and to assess changes since the period of 2003-2005. PATIENTS AND METHODS Two cross-sectional surveys of the random samples of the Polish population were performed in the years 2003-2005 (WOBASZ) and 2013-2014 (WOBASZ II). Interviews were carried out according to a standard questionnaire. Blood lipid levels were determined in a single laboratory in frozen samples using the enzymatic colorimetric method. RESULTS The analysis included 14151 participants aged 20-74 years (WOBASZ) and 5947 participants aged 20-99 years (WOBASZ II). In the 2013-2014 survey, hypercholesterolemia was found in 70.3% of men and 64.3% of women. Isolated hypertriglyceridemia was found in 5.6% of men and 2.4% of women. Isolated low levels of high-density lipoprotein cholesterol (HDL-C) were found in 5.1% of men and in 7.3% of women. The prevalence of hypercholesterolemia did not change significantly with regards to the 2003-2005 survey. An increase in the prevalence of hypertriglyceridemia was found in men (relative ratio [RR], 1.26; 95% confidence interval [CI], 1.03-1.55), and an increase in the prevalence of low HDL-C levels was observed in both sexes (men: RR, 2.26; 95% CI, 1.77-2.88; women: RR, 1.94; 95% CI, 1.61-2.33). There was an increase in the proportion of persons receiving high- or moderate-intensity statin therapy. However, 60,6% of persons with hypercholesterolemia were not aware of their condition, and only 6% were treated and achieved the treatment target.  CONCLUSIONS There is an urgent need for more effective strategies for the prevention and management of dyslipidemias.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27452484     DOI: 10.20452/pamw.3464

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  15 in total

1.  PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

Authors:  Maciej Banach; Piotr Jankowski; Jacek Jóźwiak; Barbara Cybulska; Adam Windak; Tomasz Guzik; Artur Mamcarz; Marlena Broncel; Tomasz Tomasik; Jacek Rysz; Agnieszka Jankowska-Zduńczyk; Piotr Hoffman; Agnieszka Mastalerz-Migas
Journal:  Arch Med Sci       Date:  2016-12-19       Impact factor: 3.318

2.  PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.

Authors:  Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska
Journal:  Arch Med Sci       Date:  2021-11-08       Impact factor: 3.318

3.  Cardiovascular risk and metabolic profile of Polish citizens from Lower Silesia. First signs of metabolic crisis?

Authors:  Lukasz Kozera; Wiktor Kuliczkowski; Elzbieta Gocek
Journal:  Arch Med Sci       Date:  2020-10-14       Impact factor: 3.707

Review 4.  Global epidemiology of dyslipidaemias.

Authors:  Angela Pirillo; Manuela Casula; Elena Olmastroni; Giuseppe D Norata; Alberico L Catapano
Journal:  Nat Rev Cardiol       Date:  2021-04-08       Impact factor: 32.419

5.  Association of serum levels of lipoprotein A-I and lipoprotein A-I/A-II with high on-treatment platelet reactivity in patients with ST-segment elevation myocardial infarction.

Authors:  Aleksander Siniarski; Rafal Grzybczak; Pawel Rostoff; Jaroslaw Zalewski; Urszula Czubek; Jadwiga Nessler; Grzegorz Gajos
Journal:  Anatol J Cardiol       Date:  2018-06       Impact factor: 1.596

6.  Prevalence, awareness, treatment and control of hypertension in the adult Polish population - Multi-center National Population Health Examination Surveys - WOBASZ studies.

Authors:  Arkadiusz Niklas; Anna Flotyńska; Aleksandra Puch-Walczak; Maria Polakowska; Roman Topór-Mądry; Maciej Polak; Walerian Piotrowski; Magdalena Kwaśniewska; Paweł Nadrowski; Andrzej Pająk; Wojciech Bielecki; Krystyna Kozakiewicz; Wojciech Drygas; Tomasz Zdrojewski; Andrzej Tykarski
Journal:  Arch Med Sci       Date:  2018-01-10       Impact factor: 3.318

7.  Prevalence of dyslipidemia and associated risk factors among adult residents of Mekelle City, Northern Ethiopia.

Authors:  Gebremedhin Gebreegziabiher; Tefera Belachew; Kibrti Mehari; Dessalegn Tamiru
Journal:  PLoS One       Date:  2021-02-09       Impact factor: 3.240

8.  Prevalence of cardiometabolic risk factors and selected cardiovascular diseases in hypertensive and normotensive participants in the adult Polish population: The WOBASZ II study.

Authors:  Arkadiusz Niklas; Justyna Marcinkowska; Magdalena Kozela; Andrzej Pająk; Tomasz Zdrojewski; Wojciech Drygas; Aleksandra Piwońska; Wojciech Bielecki; Krystyna Kozakiewicz; Andrzej Tykarski
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

9.  Clinical diversity in patients with Schnyder corneal dystrophy-a novel and known UBIAD1 pathogenic variants.

Authors:  Anna Sarosiak; Monika Udziela; Aneta Ścieżyńska; Dominika Oziębło; Anna Wawrzynowska; Jacek P Szaflik; Monika Ołdak
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-06       Impact factor: 3.117

10.  Correlates of Blood Pressure and Cholesterol Level Testing Among a Socially-Disadvantaged Population in Poland.

Authors:  Małgorzata Znyk; Kinga Polańska; Leokadia Bąk-Romaniszyn; Dorota Kaleta
Journal:  Int J Environ Res Public Health       Date:  2020-03-23       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.